Ignite Creation Date:
2024-05-06 @ 8:08 PM
Last Modification Date:
2024-10-26 @ 3:21 PM
Study NCT ID:
NCT06261879
Status:
RECRUITING
Last Update Posted:
2024-02-15
First Post:
2024-02-07
Brief Title:
Non-invasive Biomarker Discovery for Pre-cervical orand Cervical Cancer--ACTN4 and Other Biomarkers in Menstrual Blood
Sponsor:
WomenX Biotech Limited
Organization:
WomenX Biotech Limited
Study Overview
Official Title:
Non-invasive Biomarker Discovery for Pre-cervical orand Cervical Cancer--ACTN4 and Other Biomarkers in Menstrual Blood
Status:
RECRUITING
Status Verified Date:
2024-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The goal of this clinical trial is
1 To test the sensitivity and specificity of using ACTN4 from menstrual blood for the detection of pre-cervical orand cervical cancer
2 If ACTN4 is not a promising biomarker other biomarkers will be explored
3 To develop an effective and non-invasive detection method for pre-cervical orand cervical cancer
in Women with menstruation
The main question it aims to answer is
To validate whether menstrual blood could be used as a non-invasive means for the detection of pre-cervical or cervical cancer
Participants will
1 Join the briefing session of the study
2 Sign the consent form and health questionnaire
3 Submit the cervical medical reports within 3 months or perform sponsored pap smear test
4 Collect the menstrual blood sample
If there is a comparison group Researchers will compare The diseased group and the healthy group according to the medical reports they provided to see if ACTN4 from menstrual blood is a promising biomarker for the detection of pre-cervical or cervical cancer
1 To test the sensitivity and specificity of using ACTN4 from menstrual blood for the detection of pre-cervical orand cervical cancer
2 If ACTN4 is not a promising biomarker other biomarkers will be explored
3 To develop an effective and non-invasive detection method for pre-cervical orand cervical cancer
in Women with menstruation
The main question it aims to answer is
To validate whether menstrual blood could be used as a non-invasive means for the detection of pre-cervical or cervical cancer
Participants will
1 Join the briefing session of the study
2 Sign the consent form and health questionnaire
3 Submit the cervical medical reports within 3 months or perform sponsored pap smear test
4 Collect the menstrual blood sample
If there is a comparison group Researchers will compare The diseased group and the healthy group according to the medical reports they provided to see if ACTN4 from menstrual blood is a promising biomarker for the detection of pre-cervical or cervical cancer
Detailed Description:
First stage of study Female subjects within the age group will first attend an online research briefing session After the online briefing session the participant is provided an opportunity to join a private 1-to-1 consultation session which enables the participant to be more familiar with the details of the research content consent form study procedures and data confidentiality If they have no further questions regarding the research content consent form etc during the consultation session They will sign the consent for participating in the study they will fill in a questionnaire attached and clinic pap smear application form attached The questionnaire helps the research team to understand the subjects medical gynaecological and sexual histories a unique identifier code will be given to each subject
Second Stage of study The research team will select the subjects based on the questionnaire answers If the selected subjects have undergone pap test HPV test or coloscopy recently within 3 months they will submit the related medical record with the unique identifier number to us If the selected subjects have not undergone pap test HPV test or coloscopy recently within 3 months they will be sponsored to Pap test orand HPV genotyping orand colposcopy at the designated hospitals or clinics When their Pap test orand HPV genotyping orand colposcopy results are available they or the designated hospitals clinics will send us the related medical reports with the unique identifier number
Third Stage of Study The participants will be further selected according to the medical records submitted If the participants were selected to enter the third stage of the study the selected subjects will submit their menstrual blood to us with a unique identifier number given
Second Stage of study The research team will select the subjects based on the questionnaire answers If the selected subjects have undergone pap test HPV test or coloscopy recently within 3 months they will submit the related medical record with the unique identifier number to us If the selected subjects have not undergone pap test HPV test or coloscopy recently within 3 months they will be sponsored to Pap test orand HPV genotyping orand colposcopy at the designated hospitals or clinics When their Pap test orand HPV genotyping orand colposcopy results are available they or the designated hospitals clinics will send us the related medical reports with the unique identifier number
Third Stage of Study The participants will be further selected according to the medical records submitted If the participants were selected to enter the third stage of the study the selected subjects will submit their menstrual blood to us with a unique identifier number given
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None